…
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
CapsoVision develops and commercializes capsule endoscopy systems that capture 360-degree, internally stored images for gastrointestinal diagnostics; it operates in the medical device diagnostics industry. Long-term growth may be driven by broader adoption of non-invasive GI screening, expansion into new clinical indications and geographies, and uptake of its cloud-based image management and service model, which could support recurring revenues. Key investment risks include limited commercial scale and liquidity, intense competition from larger endoscopy players, dependence on reimbursement and regulatory approvals for new indications, and execution risk in sales and manufacturing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Income before tax | -25.29M | -19.89M | -11.29M |
| Net income | -25.32M | -19.90M | -11.30M |
| Selling general administrative | 6.85M | 4.21M | 1.97M |
| Selling and marketing expenses | 7.53M | 6.97M | 5.53M |
| Gross profit | 7.17M | 6.38M | 5.49M |
| Reconciled depreciation | 0.57M | 0.52M | 0.39M |
| Ebit | -25.52M | -19.92M | -11.35M |
| Ebitda | -24.95M | -19.40M | -10.96M |
| Depreciation and amortization | 0.57M | 0.52M | 0.39M |
| Operating income | 0.23M | -19.92M | -11.35M |
| Other operating expenses | 39.07M | 31.67M | 21.10M |
| Tax provision | 0.02M | 0.01M | 0.01M |
| Interest income | 0.27M | 0.03M | 0.05M |
| Net interest income | 0.27M | 0.03M | 0.05M |
| Income tax expense | 0.02M | 0.01M | 0.01M |
| Total revenue | 13.55M | 11.76M | 9.75M |
| Total operating expenses | 32.69M | 26.29M | 16.84M |
| Cost of revenue | 6.38M | 5.38M | 4.26M |
| Total other income expense net | -25.52M | 0.03M | 0.05M |
| Net income from continuing ops | -25.32M | -19.90M | -11.30M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Total assets | 18.16M | 16.80M | 21.53M |
| Other current assets | 1.07M | 0.90M | 0.58M |
| Total liab | 4.90M | 146.31M | 131.37M |
| Total stockholder equity | 13.26M | -129.51M | -109.84M |
| Other current liab | 2.70M | 0.50M | 0.69M |
| Common stock | 0.05M | 0.00M | 0.00M |
| Capital stock | 0.05M | 0.00M | 0.00M |
| Retained earnings | -155.66M | -130.35M | -110.45M |
| Cash | 10.11M | 9.32M | 14.56M |
| Total current liabilities | 4.43M | 1.80M | 1.51M |
| Current deferred revenue | 0.18M | 0.13M | 0.10M |
| Net debt | -9.22M | -8.08M | -13.04M |
| Short term debt | 0.41M | 0.35M | 0.28M |
| Short long term debt total | 0.89M | 1.24M | 1.51M |
| Other stockholder equity | 168.88M | -78.84M | -64.07M |
| Total current assets | 16.67M | 14.85M | 19.20M |
| Net receivables | 2.50M | 2.00M | 1.87M |
| Inventory | 2.99M | 2.63M | 2.19M |
| Accounts payable | 1.14M | 0.75M | 0.36M |
| Non currrent assets other | 0.04M | 0.04M | 0.04M |
| Non current assets total | 1.50M | 1.96M | 2.33M |
| Capital lease obligations | 0.89M | 1.24M | 1.51M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Investments | - | -0.15M | -0.75M |
| Total cashflows from investing activities | -0.09M | -0.15M | -0.75M |
| Net borrowings | 0.00M | 0.00M | - |
| Total cash from financing activities | 23.60M | 15.07M | 20.53M |
| Net income | -25.32M | -19.90M | -11.30M |
| Change in cash | 0.79M | -5.24M | 9.01M |
| Begin period cash flow | 9.32M | 14.56M | 5.55M |
| End period cash flow | 10.11M | 9.32M | 14.56M |
| Total cash from operating activities | -22.86M | -20.09M | -10.80M |
| Issuance of capital stock | 26.56M | 15.00M | 20.36M |
| Depreciation | 0.57M | 0.52M | 0.39M |
| Change to inventory | -0.36M | -0.43M | -0.67M |
| Change to account receivables | -0.48M | -0.18M | 0.01M |
| Other cashflows from financing activities | -3.18M | 15.07M | 20.53M |
| Capital expenditures | 0.09M | 0.15M | 0.75M |
| Change in working capital | 1.19M | -0.98M | 0.16M |
| Stock based compensation | 0.83M | 0.16M | 0.04M |
| Other non cash items | -0.13M | 0.11M | -0.09M |
| Free cash flow | -22.95M | -20.24M | -11.56M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| CV CapsoVision, Inc. Common Stock |
-0.10 1.57% |
6.27 | - | - | 22.99 | 24.75 | 22.85 |
| ABT Abbott Laboratories |
-1.17 1.06% |
109.29 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 |
| MDT Medtronic PLC |
0.02 0.02% |
101.61 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 |
| SYK Stryker Corporation |
-5.50 1.70% |
318.79 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 |
| SEMHF Siemens Healthineers AG |
0.30 0.63% |
48.57 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 |
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Kang-Huai Wang | Co-Founder, President, CEO & Director | 1958 |
| Mr. Douglas Atkinson | Senior Vice President of Global Sales | 1969 |
| Mr. David Garcia | Compliance Officer, SVP of Finance, Principal Financial & Accounting Officer | 1975 |
| Helen Chau | Manager of Human Resources | NA |
| Anna Krylova | Corporate Controller | NA |
| Mr. Kang-Huai Wang | Co-Founder, President, CEO & Director | 1957 |
| Mr. Douglas Atkinson | Senior Vice President of Global Sales | 1968 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.